Group | Progressive Motility (%) | Viability (%) | Acrosomal Reaction (%) | Extracellular ROS level (RLU) |
---|---|---|---|---|
HTF + 0.4%BSA | 78.33 ± 0.88a | 89 ± 0.58a | 5 ± 0.45a | 415 ± 35a |
c-TYH + 0mM MBCD | 77.67 ± 1.45a | 79.67 ± 0.88b | 4.5 ± 0.5a | 181 ± 19a |
c-TYH + 0.75mM MBCD | 73.67 ± 1.86a | 76.33 ± 1.45b | 12.33 ± 1.2b | 945 ± 45b |
c-TYH + .75mM MBCD + 20ng/ul pCAG-GFP | 76.33 ± 2.03a | 78 ± 1.16b | 12.67 ± 0.88b | 930 ± 30b |
c-TYH + .75mM MBCD + 20ng/ul pgRNA-Cas9 | 77 ± 1.53a | 78 ± 0.58b | 12 ± 1.23b | 950 ± 50b |
c-TYH + 1mM MBCD | 71.33 ± 1.33a | 74 ± 0.58b | 15 ± 0.71b | 1189 ± 10.5b |
c-TYH + 1mM MBCD + 20ng/ul pCAG-GFP | 73 ± 1a | 75 ± 0.58b | 16.33 ± 1.2b | 1160 ± 15b |
c-TYH + 1mM MBCD + 20ng/ul pgRNA-Cas9 | 73.33 ± 1.2a | 75.67 ± 0.88b | 15.67 ± 1.33b | 1201.6 ± 20b |
c-TYH + 2mM MBCD | 51 ± 1.53b | 53.33 ± 1.76c | 23 ± 1.08c | 3319.5 ± 19.5c |
c-TYH + 2mM MBCD + 20ng/ul pCAG-GFP | 51 ± 0.58b | 53 ± 0.33c | 21.67 ± 0.33c | 3330.2 ± 17c |
c-TYH + 2mM MBCD + 20ng/ul pgRNA-Cas9 | 50.33 ± 0.33b | 53 ± 0.58c | 21.33 ± 0.88c | 3350 ± 10c |
HTF + 0.4%BSA + 3%DMSO + 20ng/ul pCAG-GFP | 11.67 ± 0.88c | 44 ± 0.33d | 20.33 ± 0.33c | 3400 ± 25c |
HTF + 0.4% BSA + 3% DMSO + 20ng/ul pgRNA-Cas9 | 12.67 ± 1.45c | 45 ± 2.19d | 22 ± 1c | 3451 ± 49c |